Remove Disease Remove Pharma Companies Remove Regulations
article thumbnail

How GPCR-targeting therapies are advancing the fight against inflammatory disease

Drug Target Review

All these features make GPCRs central to regulating many vital biological processes in the body, including immune responses and inflammation, and thus especially attractive for therapeutic intervention. Moreover, it also has demonstrated involvement in barrier integrity and pain – two additional components of many inflammatory diseases.

Disease 59
article thumbnail

How AI will reshape pharma by 2025

Drug Target Review

Their work focuses on creating ‘digital twin generators’ – AI-driven models that predict how a patients disease may progress over time. These digital twins allow pharmaceutical companies to design clinical trials with fewer participants, while still providing reliable evidence to assess a drugs effectiveness.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Algae: a source for prebiotics and drugs to treat IBD

Drug Target Review

Inflammatory bowel disease (IBD) is an umbrella term that describes complex disorders that cause chronic inflammation in the digestive tract with alternating periods of relapse and remission. A changed composition of the gut microbiota is a characteristic trait of inflammatory bowel disease. More than 6.8

Drugs 75
article thumbnail

Pharma Contract Sales Outlook 2025–2030: Multilingual Teams Drive Global Expansion

The Pharma Data

As pharma companies grapple with mounting pressure from regulators, payers, and evolving market dynamics, the CSO model offers a compelling alternative to traditional, fully in-house sales forces. CNS Disorders and Autoimmune Diseases : Where nuanced communication and long-term patient management are key.

article thumbnail

H1’s Predictions for Healthcare and Pharma in 2025

H1 Blog

In 2025, I predict that there will be global regulations requiring comprehensive diversity plans for all major markets, including the EU and EMEA. As these standards take shape, pharma companies will adopt tools and models to reach broader and more diverse participants.

article thumbnail

Q&A: The IND Journey Phase I – Navigating Success

Advarra

The standard for the audit used depends on the type of vendor and would include the applicable regulations and ICH guidelines. The sponsor-initiated IND is conducted by a pharma company seeking commercial approval. The term drug substance and drug product are found in the NDA regulations 21 CFR 314.3,

article thumbnail

What type of R&D efforts are needed to develop value added medicines?

Altus Drug Development

For instance, European pediatric regulation places certain requirements to support the safety and efficacy of drugs destined to be used on children ( source ). Drug repositioning has become a strategic research approach when treating neglected diseases. To comply with the law.